ZFHX3 and non-small cell lung carcinoma: Recent work identified ZFHX3 mutations as an independent prognostic biomarker of longer OS in NSCLC patients treated with immune checkpoint inhibitors51,52, possibly explained by higher mutational burden and increased tumor immunogenicity52.